NYSE - Delayed Quote ? USD Qiagen N.V. (QGEN) Follow Compare 41.27 -0.82 (-1.95%) At close: November 15 at 4:00 PM EST 41.27 0.00 (0.00%) After hours: November 15 at 5:30 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations QGEN Collaborates With McGill University Centre: Stock to Gain? QIAGEN joins forces with McGill University Centre for Microbiome Research to generate evidence-based knowledge for medicine and public health. Zacks ? 4 days ago QGEN -1.95% GMED RMD QIAGEN collaborates with McGill University to advance microbiome research QIAGEN and McGill University to collaborate on microbiome research projects to generate evidence-based knowledge for medicine and public health // McGill will serve as a beta-testing site for new QIAGEN microbiome solutions // Partnership strengthens QIAGEN’s efforts in microbiome research while supporting innovation at the McGill Centre for Microbiome ResearchMontreal, Canada, and Venlo, the Netherlands, Nov. 12, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today GlobeNewswire ? 5 days ago QGEN -1.95% Don't Overlook Qiagen (QGEN) International Revenue Trends While Assessing the Stock Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance. Zacks ? 6 days ago QGEN -1.95% Qiagen Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags Qiagen ( NYSE:QGEN ) Third Quarter 2024 Results Key Financial Results Revenue: US$501.9m (up 5.5% from 3Q 2023). Net... Simply Wall St. ? 8 days ago QGEN -1.95% Qiagen’s Financial Growth and Rising Debt in Q3 2024 Qiagen (QGEN) has released an update. Qiagen has reported its financial results for the third quarter of 2024, showing an increase in total assets to over $6.27 billion from $6.11 billion at the end of 2023. The company’s current assets have grown significantly, with cash and cash equivalents rising to approximately $973 million. However, there has been a rise in long-term debt to $1.36 billion, highlighting potential financial strategies to watch in the coming months. For further insights into TipRanks ? 8 days ago QGEN -1.95% Why Qiagen (QGEN) is a Top Value Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. Zacks ? 9 days ago QGEN -1.95% Qiagen NV (QGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements Qiagen NV (QGEN) reports a 6% revenue growth and improved profitability, driven by robust performance in Diagnostic Solutions and QIAstat sales. GuruFocus.com ? 9 days ago QGEN -1.95% Is There An Opportunity With Qiagen N.V.'s (NYSE:QGEN) 31% Undervaluation? Key Insights The projected fair value for Qiagen is US$63.97 based on 2 Stage Free Cash Flow to Equity Qiagen's... Simply Wall St. ? 10 days ago QGEN -1.95% QIAGEN Stock Flat Post Q3 Earnings & Revenue Beat, 2024 EPS View Up QGEN delivers another solid performance in the third quarter of 2024, with both the top and bottom lines surpassing estimates. Zacks ? 10 days ago QGEN -1.95% DGX BSX Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. Zacks ? 11 days ago QGEN -1.95% Qiagen (QGEN) Q3 Earnings and Revenues Top Estimates Qiagen (QGEN) delivered earnings and revenue surprises of 5.56% and 2.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 11 days ago QGEN -1.95% Qiagen: Q3 Earnings Snapshot PL VENLO, Netherlands (AP) — Qiagen NV (QGEN) on Wednesday reported third-quarter profit of $98.1 million. On a per-share basis, the Pl Venlo, Netherlands-based company said it had profit of 44 cents. Earnings, adjusted for one-time gains and costs, came to 57 cents per share. Associated Press Finance ? 11 days ago QGEN -1.95% QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook Q3 2024: Net sales of $502 million (+5% actual rates, +6% constant exchange rates, CER); diluted EPS of $0.44 and adjusted diluted EPS of $0.57 // Net sales of $502 million CER ahead of outlook for at least $495 million CER and adjusted diluted EPS of $0.58 CER ahead of outlook for at least $0.55 CER // +10% CER growth in Diagnostic solutions leads results among product groups // 29.6% adj. operating income margin up 3 percentage points vs. 26.6% in Q3 2023 // Free cash flow up 73% to $364 milli GlobeNewswire ? 11 days ago QGEN -1.95% QGEN Stock Set to Gain From FDA's Clearance of QIAstat-Dx Mini Panel QIAGEN wins FDA clearance for the QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment. Zacks ? 13 days ago QGEN -1.95% GMED RMD Qiagen (QGEN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates Beyond analysts' top -and-bottom-line estimates for Qiagen (QGEN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024. Zacks ? 13 days ago QGEN -1.95% QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth FDA clearance marks milestone in 2024 in successful expansion of QIAstat?Dx tests developed specifically for the U.S. // QIAGEN now offers broad menu with FDA-cleared tests for respiratory, gastrointestinal and central nervous system infections – and plans for further expansion // QIAstat-Dx delivers results in about one hour with real-time PCR, e GlobeNewswire ? 13 days ago QGEN -1.95% EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock? EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. Zacks ? 19 days ago EYPT QGEN -1.95% QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment QIAstat-Dx Respiratory Panel Mini targets the five most actionable respiratory pathogens in outpatient settings to help clinicians make precise treatment decisions // With the new test and the 21-target QIAstat-Dx Respiratory Panel Plus, clinicians can fine-tune their diagnostic approach for individual patients, promoting better diagnostic stewardship // FDA decision marks third positive U.S. regulatory outcome for QIAstat-Dx to date in 2024Germantown, Maryland, and Venlo, the Netherlands, Oct. GlobeNewswire ? 19 days ago QGEN -1.95% Qiagen N.V. (NYSE:QGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? With its stock down 6.5% over the past month, it is easy to disregard Qiagen (NYSE:QGEN). However, stock prices are... Simply Wall St. ? 30 days ago QGEN -1.95% Are You a Value Investor? This 1 Stock Could Be the Perfect Pick Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. Zacks ? last month QGEN -1.95% Performance Overview Trailing total returns as of 11/15/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return QGEN S&P 500 YTD -2.02% +23.08% 1-Year +7.59% +30.58% 3-Year -20.94% +25.36%
